# H-Type Hypertension Precision Medicine Trial

Study · id `cardio:ct-nct03472508` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03472508](<https://clinicaltrials.gov/study/NCT03472508>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03472508

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3600 participants.

## Technical summary

Registry record NCT03472508. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2019-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3600 participants (planned count; ClinicalTrials.gov record NCT03472508, source copy `cardio:ctgov-nct03472508-2018-07-18`, retrieved 2026-10-26)
- Started: 2018-03-20 (actual) (ClinicalTrials.gov record NCT03472508, source copy `cardio:ctgov-nct03472508-2018-07-18`, retrieved 2026-10-26)
- Primary completion: 2019-03-30 (anticipated) (ClinicalTrials.gov record NCT03472508, source copy `cardio:ctgov-nct03472508-2018-07-18`, retrieved 2026-10-26)
- Completion: 2019-06-30 (anticipated) (ClinicalTrials.gov record NCT03472508, source copy `cardio:ctgov-nct03472508-2018-07-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03472508, source copy `cardio:ctgov-nct03472508-2018-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03472508-2018-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: H-Type Hypertension Precision Medicine Trial
- Condition: Hypertension
- Intervention (Drug): Folic Acid
- Intervention (Drug): Enalapril Maleate and Folic Acid Tablets (Yiye)
- Intervention (Drug): Enalapril
- Lead sponsor: Shenzhen Ausa Pharmed Co.,Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Second Affiliated Hospital of Nanchang University
- Collaborator class: OTHER
- Collaborator: Shenzhen Evergreen Medical Institute
- Collaborator class: UNKNOWN
- Collaborator: Nanfang Hospital, Southern Medical University
- Collaborator class: OTHER
- Collaborator: Peking University First Hospital
- Collaborator class: OTHER
- Collaborator: The First People's Hospital of Lianyungang
- Collaborator class: OTHER
- Collaborator: People's Hospital of Rongcheng
- Collaborator class: UNKNOWN
- Collaborator: Anhui Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Shenzhen Ausa Pharmed Co.,Ltd (`cardio:org-shenzhen-ausa-pharmed-co-ltd`)
- Registry lists this organization as a collaborator: Second Affiliated Hospital of Nanchang University (`cardio:org-second-affiliated-hospital-of-nanchang-university`)
- Registry lists this organization as a collaborator: Nanfang Hospital, Southern Medical University (`cardio:org-nanfang-hospital-southern-medical-university`)
- Registry lists this organization as a collaborator: Peking University First Hospital (`cardio:org-peking-university-first-hospital`)
- Registry lists this organization as a collaborator: The First People's Hospital of Lianyungang (`cardio:org-the-first-people-s-hospital-of-lianyungang`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) (`cardio:pubmed-38478042`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 32ad5b9de01e99e0cd8abfc3d73df5f66d5c3643737ed5970e7fb6d477230c6c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
